🔗 Share this article

Elected officials have issued warnings that the United Kingdom's series of deals with the US administration are "fundamentally unstable." This follows revelations that a so-called "milestone" deal on pharmaceutical tariffs, which commits to zero tariffs in exchange for the NHS facing higher prices, lacks any underlying contract beyond broad headline terms outlined by government press releases.

Lacking Legal Footing

The US-UK pharmaceuticals agreement, described as a "generational" achievement, exists as an "broad understanding" without detailed provisions. Observers point out that the official announcements from the UK and US governments present the deal in markedly contrasting terms. The British version celebrates securing "duty-free access" as a singular success, while the American announcement concentrates on the expectation for the NHS to pay significantly more for new medications.

"We face a genuine possibility that the UK government has promised concessions to raise drug prices in return for little more than a verbal promise from President Trump," commented David Henig, a trade policy analyst. "We know he has a record of not keeping promises."

Wider Concerns Amidst a Suspended Agreement

Concerns have been intensified by Washington's recent decision to suspend the major technology agreement, which was previously described as "a huge leap forward" in the bilateral relationship. The US cited a insufficient movement from the UK on reducing other tariffs as the reason for the pause.

Additionally, concessions promised for British farmers as part of an earlier tariff deal have still not been formally ratified by the US, despite a imminent January deadline. "We have been informed that that the US has failed to approve the agreed beef export quotas," said Tom Bradshaw of the National Farmers' Union.

Uncertainty Among Officials

In confidential discussions, ministers have expressed concerns that the government's deals with Washington are flimsy and unreliable. One minister reportedly said the series of agreements as "built on sand," while another described the situation as the "current reality" in the transatlantic relationship, marked by "increased uncertainty and instability."

Layla Moran, chair of the health select committee, stated: "What is even more astonishing than the US approach is the UK government's credulous faith that his administration is a good faith actor. The NHS is not a bargaining chip."

Official Reassurances and Concrete Outcomes

Officials have attempted to minimize the possibility of the US backing out of the pharmaceuticals deal. One source noted the US pharmaceutical industry itself had been advocating for the agreement, desiring stability on imports and pricing, making it of tangible value than the paused tech deal.

Officials acknowledge that unpredictability is a feature of dealing with the current US leadership. However, they contend that the UK has secured concrete outcomes for businesses, such as preferential tariff rates compared to other nations. "Securing 25% steel tariffs, which is lower than the rate for the rest of the world, is a concrete advantage," one official said.

Yet, delays have arisen in carrying out the broader trade deal. Promised access for British beef have failed to be approved, and the pledge to "reduce steel tariffs to zero" has not been fulfilled, with tariffs fixed at 25%.

As negotiations continue, the two sides have scheduled to restart talks on the paused tech prosperity deal in January, following what were described as "very positive" meetings between UK and US officials in Washington.